News
Voices of Hodgkin’s Blog
Voices of Hodgkin’s Blog

Significant Progression-Free Survival in Stage III/IV Classic Hodgkin Lymphoma

A Phase III trial has demonstrated that patients with advanced Stage III/IV classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.